



The Israeli Society for Pharmacoeconomics and Outcomes Research (ISPOR-Israel)

Israel Chapter Annual Report 2008

TO:
Board of Directors
International Society for Pharmacoeconomics and Outcomes Research
3100 Princeton Pike, Suite 3E
Lawrenceville, NJ 08648 USA

PREPARED BY:
Dan Greenberg, PhD
Department of Health Systems Management
Faculty of Health Sciences
Ben-Gurion University of the Negev
Beer-Sheva, Israel
Tel: 972-8-647-7421
Fax: 972-8-647-7634
E-mail: dangr@bgu.ac.il

Background:

The Israel Local Chapter was accepted in September 2007. The Chapter has 41 members.

The current Executive Board of the Israel Local Chapter is:

President	Dan Greenberg, PhD Department of Health Systems Management Faculty of Health Sciences, Ben-Gurion University of the Negev Beer-Sheva, Israel
President-Elect	Shmuel Klang, PhD Clalit Health Services Headquarters Tel-Aviv, Israel
Secretary	Noa Triki, MScPharm (PhD candidate) Maccabi Healthcare Services Headquarters Tel Aviv Israel
Treasurer	Barak Palatchi, BA Pfizer Israel, Herzelia Pituach, Israel

Director **Ariel Hammerman, MScPharm (PhD candidate)**
Clalit Health Services Headquarters
Tel-Aviv, Israel

Director **Moshe Leshno, MD, PhD**
Tel-Aviv University
Tel-Aviv, Israel

Director **Oren Shavit, MScPharm, PhD**
Hebrew University of Jerusalem
Jerusalem, Israel

For more information on the Israel Local Chapter, please visit the ISPOR Local Chapter
http://www.ispor.org/local_chapters/Israel/index.asp.

Enclosure: ISPOR Israel Chapter Annual Report 2008

Israel Chapter Annual Report 2008

The 2nd Annual Conference of ISPOR-Israel

The 2nd Annual Conference of ISPOR-Israel was held on September 18-19, 2008 in hotel Dan Panorama in Jerusalem. The 140 conference attendees and speakers included participants from HMOs, academia and research institutes, the Ministry of Health, pharmaceutical and medical device companies and the media. The conference program (in Hebrew and English) can be found at the conference website: <http://www.reg.co.il/ispor/index.html>, and as an appendix to this document.

The main theme of this year's conference was "**The value of anti-cancer drugs**". We were honored to host four distinguished speakers from the United Kingdom, United States, and Canada:

Prof. Mike Drummond from the University of York presented the European perspective on the costs and cost-effectiveness of cancer therapies, and the assessment and recommendations of cancer drugs by NICE in the UK. **Dr. Chris Pashos**, ISPOR 2008-2009 president, presented the methods for assessment of Health-related Quality of Life in Cancer. **Dr. Vardit Ravitsky**, Senior Ethics Policy Advisor, Canadian Institutes of Health Research addressed the considerations for reimbursement approval of new anti-cancer drugs in Canada, and **Dr. Mel Walker**, Director of Global Health Outcomes, Oncology for GlaxoSmithKline discussed the industry perspective on the pricing and reimbursement of anti-cancer drugs.

The Annual Meeting of ISPOR-Israel Members' Assembly

According to its constitution, **ISPOR-Israel** held its annual meeting of the members' assembly on September 18, 2008. During this meeting, we discussed ideas to promote the field of pharmacoconomics and outcomes research in Israel and to enhance the involvement of health practitioners in **ISPOR-Israel** activities. The annual financial report was presented and approved. The executive committee officers were re-elected for a term of one year. The assembly also elected an audit committee of two **ISPOR-Israel** members

Media Coverage and Report on ISPOR-Israel Activities

Dr. Orna Tal, an **ISPOR-Israel** member authored an article summarizing reflections from **ISPOR-Israel** first Annual Conference. The paper has been published in the May 2008 issue of "Harefuah", the Journal of the Israel Medical Association (in Hebrew). The journal is distributed to the vast majority of physicians practicing in Israel.

The 2nd Annual Conference of **ISPOR-Israel** and the meeting deliberation were covered by Ronny Linder-Gantz, a health journalist for "TheMarker", one of the largest daily economic newspapers in Israel. Two of the published articles are attached as an appendix to this report.

An interview with Dr. Dan Greenberg on **ISPOR-Israel** mission and activities appeared in the September-October 2008 issue of "The Pharma", a bi-monthly journal distributed to pharmacists and family physicians in Israel

2009 Upcoming Activities

The 3rd Annual Meeting of ISPOR-Israel is planned for September-October 2009. Additional activities planned are: a one day conference on issues relating to co-payment for pharmaceuticals and methods to improve adherence to treatment.

ISPOR-Israel members are planning to present their scientific work at the ISPOR 14th Annual International Meeting and the ISPOR 12th Annual European Congress.



The Israeli Society for Pharmacoeconomics and Outcomes Research (ISPOR-Israel)

Appendix to the 2008 Annual Report

Abbreviated Program of the ISPOR-Israel 2nd Annual Meeting

Thursday, September 18, 2008

08:30 - 09:30 Registration

09:30 - 09:45 Welcome & Introduction
Prof. Joshua Shemer
Prof. Joseph Pliskin
Dr. Boaz Lev

09:45 - 10:00 Welcome from ISPOR
Dr. Chris L. Pashos, 2008-2009 ISPOR President

10:00 - 11:00 A European perspective on the costs and cost-effectiveness of cancer therapies
Prof. Mike Drummond, University of York

11:00 - 11:30 Coffee Break

SESSION I

11:30 - 13:00 Reimbursement of anti-cancer drugs.
Chair: Prof. Joshua Shemer

11:30 - 12:15 Pricing and reimbursement of anti-cancer drugs: the industry perspective
Dr. Mel Walker, Director, Global Health Outcomes, Oncology, GlaxoSmithKline.

12:15 - 13:00 Considerations for reimbursement approval of new anti-cancer drugs - the Canadian experience
Dr. Vardit Ravitsky, Senior Ethics Policy Advisor, Canadian Institutes of Health Research

13:00 - 14:00 Lunch Break

SESSION II

14:00 - 16:45 Physicians' and patients' perspective of anti-cancer drugs cost & effectiveness.
Chair: Prof. Adi Shani

14:00 - 14:30 Oncologists priorities for improving the cancer treatment system
Dr. David Chinitz

14:30 - 15:00 Do patients understand the true costs, risks & benefits of cancer treatment?
Mrs. Eti Samama
Mr. Meidad Gissin

15:00 - 16:15 Issue Panel I:
Should patients have access to effective cancer care regardless of cost?
Chair: Prof. Gabi Ben-Nun
Dr. Ehud Kukia
Prof. Noam Zohar
Rabbi Yuval Cherlow
Prof. Baruch Klein
Mr. David Goren
Mrs. Miri Ziv

16:15 - 16:45 Coffee Break

SESSION III

- 16:45 - 18:00 **Contributed Podium Presentations – Session I**
Chairs: Dr. Amir Shmueli & Dr. Segev Shani
- 16:45 - 17:00 Expenditure on Anti-Cancer Drugs Compared to Other Drugs in the Past Decade.
Lomnický Y, Ziegelman-Danieli N, Wasterman-Landes J, Katzir Y, Kukia E, Maccabi Health Services.
- 17:00 - 17:15 The Cost and Feasibility of a Prostate Cancer Early Detection Program in Gastroenterology Units: The Experience of the Hadassah Ein-Kerem Medical Center
Shafrań-Tikva S^{1,2}, Lysy Y¹, Goldin E¹, Greenberg D² ¹Gastroenterology Unit, Hadassah University Medical Center Ein Kerem, Jerusalem.²Department of Health Systems Management, Ben-Gurion University of the Negev, Beer-Sheva.
- 17:15 - 17:30 The Impact of Oncotype Dx[®] Assay Use on Real Life Treatment Decisions in N-, ER+ Early-Stage Breast Cancer Patients: It's Implication For Budget Impact Analysis.
Hammerman A¹, Klang SH¹, Liebermann N¹, Merling S¹ Efrat N² ¹Clalit Health Services Headquarters, Tel-Aviv, ²Kaplan Medical Center, Rehovot.
- 17:30 - 17:45 Cost Effectiveness of Treating Colorectal Cancer With Cetuximab As a 3rd Line Therapy Using K-Ras Mutation Status as an Inclusion Criteria
Ginzburg B, e-Med.
- 17:45 - 18:00 Economic Evaluation of Fulvestrant (Faslodex[®]) As an Additional Endocrine Step in the Treatment Sequence For Hormone-Receptor Positive Advanced and Metastatic Breast Cancer In Israel
Greenberg D¹, Rabinovich M², Hirsch M³ ¹Department of Health Systems Management, Ben-Gurion University of the Negev, Beer-Sheva. ²AstraZeneca (Israel) Ltd., Ra'anana, ³AstraZeneca Pharmaceutical Ltd.
- 19:00 **Dinner & Evening tour of Jerusalem**

Friday, September 19, 2008

SESSION IV

- 08:30 - 11:10 **Chair: Prof. Avi Porath**
- 08:30 - 09:10 Assessment and recommendations of cancer drugs by NICE in the UK
Prof. Mike Drummond, University of York
- 09:10 - 09:50 Assessment of Health-related Quality of Life in Cancer
Dr. Chris L. Pashos, 2008-2009 ISPOR President
- 09:50 - 11:00 Issue Panel II:
Physicians' recommendations for non-reimbursed therapies: Is the Israeli Law of Patients Rights an ethical obstacle for the treating oncologist?
Chair: Prof. Alik Aviram
Prof. Rafi Catane
Dr. Bella Kaufman
Dr. Nicky Liebermann
Dr. Shai Feuring
Dr. Udi Kantor
- 11:00 - 11:20 Coffee Break

SESSION V

- 11:20 - 12:50 **Contributed Podium Presentations- Session II**
Chairs: Dr. Moshe Leshno & Dr. Yossi Lomnicki
- 11:20 - 11:35 Clinical & Economical Impact of a Centralized Pre-Authorization Mechanism for Erythropoietin
Katzir Y, Wasterman-Landes J, Karol R, Bialik M, Lomnicki Y, Maccabi Health Services.
- 11:35 - 11:50 Cost-Effectiveness Analysis of a Drug-Drug Interactions Alert System
Appleboim R¹, Hammerman A², Klang SH², Leshno M¹ ¹The Faculty of Management, Tel Aviv University, ²Clalit Health Services Headquarters, Tel-Aviv
- 11:50 - 12:05 A Cost Effectiveness Analysis of Botulinum Toxin A (Dysport) For the Treatment of Upper Arm Spasticity In Post Stroke Patients
Leshno M. Tel-Aviv University, Tel-Aviv
- 12:05 - 12:20 Cost Effectiveness of Secondary Prevention of Stroke In Israel Using Dipyridamole+Aspirin In Comparison With Aspirin Only
Ginzburg B, e-Med.
- 12:20 - 12:35 Cost Utility Analysis of Vaccination Against HPV In Israel
Ginsberg GM¹, Fisher M², Ben-Shahar P, Bornstein J⁴, ¹Medical Technology Assessment Sector, Ministry of Health, Jerusalem. ²Clalit Health Services, Nahariya ³Department of Gynecology. Hadassah Medical Center, Mount-Scopus, Jerusalem ⁴Department of Obstetrics and Gynecology, Western Galilee Hospital, Nahariya, and Rappaport Faculty of Medicine, Technion, Haifa, Israel
- 12:35 - 12:50 Treating Patients with Microsatellite Instable Colorectal Tumors - the Economic Point of View.
Rennert G¹, Regev S², ¹Carmel Medical Center, Haifa, ²Planning and Health Policy Division, Clalit Health Services Headquarters, Tel-Aviv
- 12:50 -13:30 **Closing Remarks.**
Dr. Shmuel Klang, Dr. Dan Greenberg
- 13:30 - 14:30 Lunch